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Antifungal susceptibilityAbstract Vulvovaginal candidiasis (VVC) remains one of the most common infections of the
female genital tract. Correct identification of the isolated Candida species is essential to direct the
empirical antifungal therapy. Objectives: This local study was conducted to identify the spectrum
of Candida species associated with VVC using different phenotypic and genotypic methods and
assess their antifungal susceptibility pattern. Materials and methods: High vaginal swabs were col-
lected from 125 patients presenting with a clinical picture suggestive of VVC. Swabs were subjected
to Gram-stain and culture on Sabouraud dextrose agar. Species identification of Candida isolates
was done using phenotypic methods including germ tube test, Rice Tween-80 agar, Chrom ID
(CAN2) agar and API 20C AUX, while PCR-RFLP was used as the gold standard method.
Antifungal susceptibility testing was done using the disk diffusion method. Results: Vaginal swab
cultures yielded Candida growth in 63 cases (50.4%). Candida albicans was the predominant isolated
species (60.3%) while the most common non-albicans species was Candida glabrata (12.7%). Forty-
five (71.4%) and fifty-five (87.3%) Candida isolates were correctly speciated by Rice Tween-80 Agar
and API 20C AUX, respectively, while fifty-seven isolates (90.5%) were correctly assigned into the 3
groups of yeasts identified by CAN2 agar. Amphotericin B was more effective than azoles against
vaginal Candida isolates. Conclusion: C. albicans is the most common species associated with VVC.
API 20C AUX was the most accurate phenotypic method for the proper identification of most
Candida species whereas PCR-RFLP could properly confirm Candida species identification
genotypically.
 2015 The Authors. Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Table 1 Size of ITS1-ITS4 PCR products before and after
digestion with MspI.17
Candida species Size of ITS1-ITS4 (bp) Size of restriction
products (bp)
C. glabrata 871 557 and 314
C. guilliermondii 608 371,155 and 82
C. albicans 535 297 and 238
C. tropicalis 524 340 and 184
C. parapsilosis 520 520
C. krusei 510 261 and 249
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Vulvovaginal candidiasis (VVC) is a common disorder in
women.1,2 The majority of cases of VVC are caused by
Candida albicans; however, episodes due to non-albicans spe-
cies of Candida appear to be increasing in immunodeficient
as well as healthy women.3 The most commonly implicated
non-albicans species include Candida glabrata, Candida
tropicalis, Candida krusei and Candida parapsilosis.4 Azoles
are the treatment of choice for VVC; however, resistance has
been reported especially in non-albicans Candida species.5,6
Because of the different susceptibility of Candida species to
antifungal agents, it is important to identify the causative
Candida to the species level correctly7; however, conventional
methods are time-consuming and may lead to misdiagnosis
among closely related species. Therefore, molecular methods
may provide a rapid and accurate alternative.8–10
2. Aim of the work
This local study was conducted to identify the spectrum of
Candida species associated with VVC using different pheno-
typic and genotypic methods and assess their antifungal sus-
ceptibility pattern.
3. Materials and methods
The study has been approved by the Research and Ethical
Committee of Medical Microbiology and Immunology
Department, Faculty of Medicine, Cairo University. Informed
consent was obtained from all individual participants included
in the study.
3.1. Specimen collection
High vaginal swabs were collected from 125 married patients
in the reproductive age period presenting to the Obstetrics
and Gynecology outpatient clinics of Cairo University
Hospitals during the period from January through June 2011
with a clinical picture suggestive of VVC. Patients who were
non-married, outside the reproductive age period or using
any systemic or local antifungal therapy in the previous month
were excluded from the study.
3.2. Specimen processing
Vaginal swab specimens were subjected to direct Gram-stained
smear examination as well as culture on Sabouraud dextrose
agar (SDA) (Oxoid, UK) incubated at 37 C for 24–48 h. Iso-
lates on SDA were identified as Candida by colony morphol-
ogy and Gram staining.
3.3. Phenotypic identification of Candida species
Candida isolates were speciated phenotypically by germ tube
test (GTT),11 Rice Tween-80 agar performed as described in
previous studies,12 in addition to Chrom ID Candida
Agar (CAN2) (BioMe´rieux, France) and API 20C AUX
(BioMe´rieux, France), which were performed according to
manufacturers’ instructions. The Candida isolates were thenstored in glycerol broth at 70 C for further processing by
PCR-restriction fragment length polymorphism (PCR-RFLP).
3.4. Genotypic identification of Candida species
Genotypic identification by PCR-RFLP was used as the gold
standard method for Candida species identification in the cur-
rent study.13,14 C. albicans standard strain (ATCC 10231) sup-
plied by Egypt Microbial Culture Collection (EMCC), Faculty
of Agriculture, Ain-Shams University, was used as a positive
control in both PCR and RFLP.
3.4.1. DNA extraction
DNA extraction was performed using QIAamp DNA Mini kit
(Qiagen) proceeded by cell disruption using tissue homoge-
nizer.15 Briefly, multiple fresh pure colonies of Candida were
dissolved in 500 lL sterile distilled water in a sterile 1.5 mL
microcentrifuge tube. Then, Candida cells were disrupted using
tissue homogenizer (Qiagen) for 3 min followed by centrifuga-
tion at 13,000 rpm for 3 min. The sediment was then subjected
to DNA extraction using QIAamp DNAMini kit according to
manufacturer’s instructions.
3.4.2. PCR
The ITS-1 and ITS-2 regions of Candida spp. were amplified
using universal primers; ITS-1(50-TCC GTA GGT GAA
CCT GCG G-30) and ITS-4 (50-TCC TCC GCT TAT TGA
TAT GC-30).16,17 The amplification was performed in Biome-
tra T 3000 Thermal cycler as previously published18 with mod-
ifications in the concentration of each primer (50 pmol/
reaction) and DNA template (5 lL extracted DNA/reaction),
in addition to change the annealing temperature (53 C).
Amplified PCR products were run on 2% agarose gel elec-
trophoresis and visualized by UV transilluminator (Biome-
traTi 3).
3.4.3. RFLP analysis
1 lL MspI enzyme 5000 units (BioLabs, England) and 2 lL
enzyme buffer (NEB buffer 4) were added to 7 lL of each
PCR product. Incubation at 37 C for 16 h was done.18
Restriction fragments were separated by 3% agarose gel elec-
trophoresis and interpretation was done accordingly17 as
shown in Table 1.
3.5. Antifungal susceptibility testing
The Candida isolates were tested by disk diffusion method
using Muller-Hinton agar supplemented with 2% glucose
Table 2 Interpretive break points of different antifungal
drugs.
Drug Susceptible
(mm)
Susceptible dose
dependent (SDD)
Resistant
(mm)
Refs.
Fluconazole
(25 lg)
P19 15–18 mm 614 19,21
Voriconazole
(1 lg)
P17 14–16 mm 613 6,19
Ketoconazole
(50 lg)
>20 10–20 mm <10 6
Miconazole
(50 lg)
>20 10–20 mm <10 6
Clotrimazole
(50 lg)
>20 12–19 mm 610 20
Amphotericin
B (100 lg)
>10 – 610 6
Table 3 Comparison between the sensitivity, specificity, PPV
and NPV of the different methods used in the study for Candida
species identification using RFLP as the gold standard.
Method Sensitivity
(%)
Specificity
(%)
PPV (%) NPV (%)
Colony morphology on SDA
C. albicans 100 88 92.7 100
C. glabrata 87.5 100 100 98.2
C. krusei 100 94.8 62.5 100
C. tropicalis 75 84.8 25 98
Germ tube testa 86.8 80 86.8 80
Rice-Tween-80
C. albicans 94.7 72 83.7 90
C. glabrata 62.5 96.4 71.4 94.6
C. krusei 20 96.6 33.3 93.3
C. tropicalis 50 91.5 28.6 96.4
C. parapsilosis 20 100 100 93.6
C.
guilliermondii
0 98.3 0 95.2
API 20C AUX
C. albicans 89.5 96 97.1 85.7
C. glabrata 62.5 100 100 94.8
C. krusei 100 96.6 71.4 100
C. tropicalis 100 93.2 50 100
C. parapsilosis 100 100 100 100
C.
guilliermondii
66.7 98.3 66.7 98.3
a For C. albicans and C. dubliniensis.
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ulated by using a swab dipped in a cell suspension adjusted to
the turbidity of 0.5 McFarland standard.19 The following anti-
fungal disks were used: fluconazole (25 lg), voriconazole
(1 lg), ketoconazole (50 lg), clotrimazole (50 lg), miconazole
(50 lg) and amphotericin B (100 lg) (BioRad). Inhibition
zones were interpreted using validated CLSI interpretive break
points for fluconazole and voriconazole, while for other drugs,
the interpretive break points were adopted from published
studies (Table 2).6,20,21
3.6. Statistical analysis
Data were statistically described in terms of frequencies and
percentages. Comparison between the study groups was done
using Chi square (v2) test. Exact test was used instead when
the expected frequency is less than 5. Accuracy was represented
using the terms sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV) and overall accuracy.
P-value was considered statistically significant if less than
0.05. All statistical calculations were done using computer pro-
gram Statistical Package for the Social Science (SPSS; SPSS
Inc., Chicago, IL, USA) version 15 for Microsoft Windows.
4. Results
Culture on SDA was the gold standard method for the diagno-
sis of VVC in the current study.22 Accordingly, out of the 125
symptomatic patients included in the present study, 63 (50.4%)
were positive for VVC. Direct Gram-stained smear was posi-
tive in only 13.6% of specimens with sensitivity, specificity,
PPV and NPV of 26.98%, 95.16%, 85% and 56.19%,
respectively.
Considering PCR-RFLP as the gold standard test for
Candida species identification,13,14 C. albicans was the
predominant isolated species (38 isolates, 60.3%), followed by
C. glabrata (8 isolates, 12.7%), C. krusei and C. parapsilosis, (5
isolates for each species, 7.9%), C. tropicalis (4 isolates, 6.3%)
and lastly, Candida guilliermondii (3 isolates, 4.8%). Methods
used for species identification in this study were unable to
differentiate between C. albicans and Candida dubliniensis.
Sensitivity, specificity, PPV and NPV of the different
methods used for speciation of Candida isolates are shown in
Table 3.4.1. Colony morphology on SDA
In the current study, it was observed that colony morphology
on SDA may help in the identification of Candida species
(Fig. 1). All C. albicans isolates grew as convex dome-shaped
pearl-like colonies on SDA. Moreover, 7 of 8 C. glabrata
isolates (87.5%) produced colonies with dark center and light
periphery. All C. krusei isolates grew as irregular colonies with
mycelial fringe. Three isolates of the 4 C. tropicalis (75%)
produced umbilicated colonies. However, C. parapsilosis and
C. guilliermondii had no specific colony morphology.4.2. Germ tube test (GTT)
GTT was positive in 38 isolates; however, only 33 of them were
identified as C. albicans by PCR-RFLP.
4.3. Subculture on Rice Tween-80 agar
Microscopic appearance of the different Candida species
isolated in this study on Rice-Tween-80 agar was interpreted
according to earlier studies.23 Forty-five (71.4%) of the 63
Candida species isolates were correctly identified by Rice
Tween-80 Agar.4.4. Chrom ID Candida agar (CAN2)
This chromogenic medium can differentiate between 3 groups
of Candida. The first group includes C. albicans; the second
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Figure 2 PCR products before digestion with restriction enzyme
MSP I. Lanes (1, 2): C. tropicalis (band at 524), Lane (3):
C. albicans (band at 535), Lane (4): C. glabrata (band at 871),
Lane (5): C. parapsilosis (band at 520), Lane (6): C. krusei (band at
510), Lane (7): C. guilliermondii (band at 608) and Lane (M): 50 bp
DNA ladder.
a b c d
Figure 1 Colony morphology of different Candida species on SDA: a – C. albicans, b – C. glabrata, c – C. krusei and d – C. tropicalis.
272 D.S. ElFeky et al.includes C. tropicalis, Candida lusitaniae and Candida kefyr,
while the third includes the rest of Candida species. Fifty-
seven (90.5%) of the Candida isolates in this study were cor-
rectly assigned into 3 groups by CAN2 agar.
4.5. API 20C AUX
Fifty-five (87.3%) of the 63 Candida isolates were correctly
identified to the species level by API 20C AUX.
4.6. PCR-RFLP
Discrete bands of 510–870 bp were obtained from amplifica-
tion of the ITS-1 and ITS-2 regions of all isolated Candida spe-
cies using the universal primers; IST-1 and IST-4. However, as
previously published,17 only bands of C. glabrata (871 bp) and
C. guilliermondii (610 bp) could be distinguished from bands of
other species which were difficult to be differentiated from
each other (510–535 bp) (Fig. 2). Thus, while PCR was suffi-
cient for the identification of C. glabrata and C. guilliermondii,
the RFLP technique using the restriction enzyme Msp I was
used for the identification of additional four Candida species:
C. albicans, C. tropicalis, C. krusei, and C. parapsilosis
(Fig. 3a and b). There is no recognition site for this enzyme
within ITS region of C. parapsilosis; therefore, the same band
(520 bp) was obtained before and after digestion with Msp I
enzyme. Repeated testing of the isolates was found to yield
consistent results.4.7. Antifungal susceptibility testing (Table 4)
The most effective antifungal agent used in this study was
amphotericin B, where 62 isolates (98.4%)-all except for
one C. parapsilosis isolate-were sensitive to it, followed by
ketoconazole (54 sensitive isolates, 85.7%), voriconazole
(52 sensitive isolates, 82.5%), fluconazole (49 sensitive iso-
lates, 77.8%), clotrimazole (39 sensitive isolates, 61.9%)
and finally miconazole (32 sensitive isolates, 50.8%). No
resistance was detected for ketoconazole, clotrimazole and
miconazole, while 7 isolates (11.1%) were resistant to flu-
conazole, 5 isolates (7.9%) were resistant to voriconazole
and 1 isolate (1.6%) was resistant to amphotericin B. Sus-
ceptible dose dependent (SDD) isolates were detected for
miconazole (31 isolates, 49.2%), clotrimazole (24 isolates,
38.1%), ketoconazole (9 isolates, 14.3%), fluconazole (7 iso-
lates, 11.1%) and voriconazole (6 isolates, 9.5%).5. Discussion
The current local study was designed to identify the spectrum
of Candida species associated with VVC in a group of 125
patients presenting with vaginal discharge and to assess their
antifungal susceptibility pattern. Rate of prevalence of VVC
was 50.4% among the studied group. Microscopic examina-
tion was not adequate for the diagnosis of VVC in the current
study, with a poor sensitivity (26%) but excellent specificity
(95.16%). Therefore, as previously reported, a negative smear
result does not rule out the presence of disease.24
Precise identification of Candida at the species level is essen-
tial because of emergence of new pathogen species and because
of the different antifungal susceptibility profiles.7,25,26 PCR-
PFLP was used in the current study as the gold standard
method for Candida species identification.13,14 C. albicans
was the most common isolated species (60.3%), whereas the
overall prevalence of non-albicans species was 39.7%. Earlier
report from Egypt27 has recorded higher rate of C. albicans
in VVC (86.6%), while rates of 59%, 65.95% and 73.9% were
reported from Saudi Arabia,28 Yemen29 and Kuwait,30 respec-
tively. Worldwide, rates of the isolation of C. albicans in cases
of VVC ranged between 47% and 89% in studies from
Nicaragua31, Australia,32,33 Turkey,34 Iran,35 Nigeria36,37 and
India.38 In these studies, there was an increasing rate of
non-albicans species in the more recent studies even in the
same country, which possibly could be attributed to a wide
spread resistance, inappropriate use of antifungal medications,
long term treatments and the use of over-the-counter antimy-
cotics.39–41 Similar to the current study, C. glabrata was the
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Figure 3 PCR-RFLP products of Candida species using MSP I enzyme. (a): Lanes (1, 2): C. guilliermondii (3 bands at 80, 150, 350 bp),
Lanes (3, 4, 6): C. albicans (2 bands at 238, 297 bp), Lane (5): C. glabrata (2 bands at 550, 314 bp), Lane (7): positive control (C. albicans
reference strain ATCC 10231), Lane (8): negative control and Lane (M): 100 bp DNA ladder (Qiagen). (b): Lane (1): C. krusei (2 bands at
261, 249 bp), Lane (2): C. glabrata (2 bands at 550, 314 bp), Lane (3): C. parapsilosis showing 1 band at 520 bp, Lane (4): C. tropicalis (2
bands at 180, 340 bp), Lane (5): C. albicans (2 bands at 238, 297 bp) and Lane (M): 100 bp DNA ladder.
Table 4 Antifungal susceptibility profile of the different isolated Candida species.
Amphotericin B (%) Fluconazole (%) Voriconazole (%) Ketoconazole (%) Miconazole (%) Clotrimazole (%)
S DD R S DD R S DD R S DD R S DD R S DD R
C. albicans 100 0 0 89.5 0 10.5 89.5 0 10.5 92.1 7.9 0 71.1 28.9 0 78.9 21.1 0
C. glabrata 100 0 0 50 50 0 50 50 0 50 50 0 37.5 62.5 0 12.5 87.5 0
C. tropicalis 100 0 0 100 0 0 75 25 0 100 0 0 50 50 0 50 50 0
C. krusei 100 0 0 20 40 40 100 0 0 100 0 0 0 100 0 80 20 0
C. parapsilosis 80 0 20 60 20 20 60 20 20 60 40 0 0 100 0 0 100 0
C. guilliermondii 100 0 0 100 0 0 100 0 0 100 0 0 0 100 0 66.7 33.3 0
Total 98.4 0 1.6 77.8 11.1 11.1 82.5 9.5 7.9 85.7 14.3 0 50.8 49.2 0 61.9 38.1 0
S = sensitive, DD= susceptible dose dependent, R = resistant.
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Saudi Arabia (31%),28 Turkey (34.5%),34 and Australia
(20%).33 Studies have reported rates of C. tropicalis isolation
in VVC ranged from 4% to 26.4%27,31,38 while rates of
C. Krusei ranged from 3% to 15.7%.28,31,34,38 Reported rates
of isolation of other species were 0.6% for C. parapsilosis28;
0.6% and 3.6% for C. kefyr28,34 while rates of isolation of
C. dubliniensis ranged from 0.17% to 29.52%.2,38
Although it has been reported that colonies of different
yeast species on SDA cannot easily be distinguished from each
other,42 however, in the current study, colony morphology on
SDA was found to be helpful in the identification of Candida
species.
Traditionally, the preliminary identification of C. albicans
was made through the use of the GTT.43 However, this test
gives also positive results in case of C. dubliniensis.44 Consis-
tent with our GTT results, some studies45,46 reported similar
sensitivity rates but with 100% specificity. Other studies47
reported lower sensitivity and specificity rates (79.3% and
69.2%, respectively), or higher rates ranging from 92 to
98.8% and 99 to 100%, respectively.23,27,48,49 Limitations of
this test include misinterpretation of elongated blastoconidia
as germ tube, absence of germ tube production in some strains
of C. albicans, and health hazards of handling pooled
sera.10,49,50
Morphological media as Rice agar-Tween 80 were used for
the differentiation of Candida species on the basis of mycelial
characteristics, size and shape of pseudohyphae and the
arrangement of blastoconidia along pseudohyphae.51 In thecurrent study, 71.4% of Candida species were correctly identi-
fied by Rice Tween-80 Agar. However its sensitivity for C. guil-
liermondii, C. krusei and C. parapsilosis was very poor (0%,
20% and 20%, respectively). Contrary to our results, other
investigators52,53 reported that morphology on morphologic
media was sufficient to make a final identification.
Chromogenic culture media are very useful for the diagno-
sis of Candida54 but their main limitation is the low discrimina-
tion power among Candida species.55 In this study, 90.5% of
Candida isolates were correctly assigned into the three groups
of yeasts identified by CAN2 agar. However, this medium was
actually useful for the identification of C. albicans with excel-
lent sensitivity and specificity, while it showed lower sensitivity
but excellent specificity for C. tropicalis (neither C. kefyr nor
C. lusitaniae were isolated in this study). The other Candida
species cannot be differentiated from each other by this med-
ium. Our results were in accordance with other studies.56,57
The most convenient and popular methods for Candida
species identification consist of commercially available strips
for carbohydrate assimilation and/or enzyme detection.56 In
the present work, 87.3% of the Candida isolates were correctly
identified to the species level by API 20C AUX. Other studies
have reported almost similar results.58–61
The standard phenotypic methods used to identify clinical
isolates of Candida species are time-consuming and not
appropriate for rapid, accurate and reliable identification.7,62
In addition, these techniques rely on phenotypic expression
that makes them potentially unreliable due to documented
phenotypic switching of Candida species.3,63,64 Consequently,
274 D.S. ElFeky et al.genotype-based approaches may be preferable for Candida
species identification.16,18,65 Currently, PCR-RFLP is the most
commonly used method for identification of Candida species.25
Other molecular methods that have been developed for rapid
diagnosis of Candida species include random amplified poly-
morphic DNA (RAPD), DNA sequence analysis and real-
time PCR.66–68 However, these methods are expensive and
need skilled workers.18.
As previously reported,16,17,62 the PCR-RFLP assay used in
this study enables the identification of six medically important
Candida species which represent up to 95% of Candida infec-
tion.17 In addition, some investigators16,69,70 have reported
that, C. kefyr and C. famata (which were not isolated in the
current study) can also be identified using the same protocol
used in this study by the size of their PCR products. However,
additional enzymes are still needed for the differentiation of C.
albicans and C. dubliniensis as both species have similar RFLP
profile when using Msp I.17,71
Several studies have used the PCR-RFLP method for the
identification of Candida species using the same single restric-
tion enzyme (Msp I) used in the current study3,7,18,69,70,72 or a
different restriction enzyme (Hae III).73 However, the later
enzyme had a lower discrimination power.73 Other studies
have used combination of Msp I and Bln I enzymes which
enabled the additional differentiation between C. albicans
and C. dubliniensis,71,74 while others16,62 reported that the com-
bination of Hae III, Dde I and Bfa I restriction enzymes
enabled the additional identification of C. stellatoidea.
In the current study, in-vitro susceptibility was performed
by the disk diffusion method. Several studies have similarly
reported that amphotericin B was the most effective drug
against vaginal Candida isolates.6,38,75,76 Although some stud-
ies have reported that ketoconazole was the most effective
azole,27,75,77 as the case in our study, however, since July
2013, the U.S. Food and Drug Administration (FDA) cleared
that ketoconazole oral tablets can cause severe liver injuries,
adrenal gland problems and harmful drug interactions with
other medications and should not be a first-line treatment
for any fungal infection. However, the topical formulations
of the drug have not been associated with such side effects.78
In accordance with our results, similar rates of fluconazole
resistance were reported in studies from Egypt27 and Taiwan.79
Higher resistance rates were reported in studies from Brazil
(32%)6 and India (16% for C. albicans)38; while no fluconazole
resistance or a very low level of resistance (0.6%) among vagi-
nal C. albicans isolates was reported in other studies from Aus-
tralia and Kuwait, respectively.30,80 It has been noted that no
resistance to fluconazole was reported among Candida vaginal
isolates in earlier studies conducted in several countries such as
US, Italy, Brazil and England.81–87 As C. dubliniensis more
easily develops fluconazole resistance than C. albicans,88 the
high azole resistance rate detected for C. albicans in this study
might be due to undifferentiating C. albicans and C. dublinien-
sis. In addition, some investigators6 have reported a high resis-
tance rate for fluconazole (32%) by disk diffusion method,
while no resistance to the drug was detected by the standard
microdilution method.
Although C. krusei is intrinsically resistant to fluconazole,5
only 40% of the isolates in this study were found to be resis-
tant and Candida species exhibited a considerable azole
cross-resistance as previously reported.89–94 Therefore, the
azole resistance rate reported in this study warrants furtherinvestigation to reassess the usefulness of fluconazole as the
most common drug used for the treatment of VVC.6. Conclusion
C. albicans was the predominant isolated species (60.3%) while
the most common non-albicans species was C. glabrata
(12.7%). API 20C AUX was an accurate phenotypic method
for Candida species identification, while Chrom ID Candida
agar was an effective method for presumptive identification
of C. albicans. The PCR-RFLP analysis was relatively simple
to perform, rapid and highly valuable; however, its direct use
on clinical samples has to be evaluated in further studies for
more rapid diagnosis. Candida antifungal susceptibility testing
is recommended to avoid treatment failures.
Limitations of the study include the lack of differentiation
of C. albicans and the closely related species C. dubliniensis
and the use of PCR-RFLP for the identification of clinical
Candida isolates rather than using it directly on clinical
specimens.Conflict of interest
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